Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
As of today, Regeneron(REGN) shares are valued at $724.21. The company's market cap stands at 76.02B, with a P/E ratio of 17.76 and a dividend yield of 47.4%.
On 2025-12-03, Regeneron(REGN) stock traded between a low of $720.14 and a high of $744.23. Shares are currently priced at $724.21, which is +0.6% above the low and -2.7% below the high.
The Regeneron(REGN)'s current trading volume is 1.24M, compared to an average daily volume of 1.24M.
In the last year, Regeneron(REGN) shares hit a 52-week high of $800.99 and a 52-week low of $476.49.
In the last year, Regeneron(REGN) shares hit a 52-week high of $800.99 and a 52-week low of $476.49.
REGN News
Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Inv...
In early trading on Wednesday, shares of Applovin topped the list of the day's best performing components of the Nasdaq 100 index, trading up 9.3%. Year to date...
Regeneron Pharmaceuticals (REGN) has caught investor attention recently, with its stock navigating some modest ups and downs this month. Returns over the past t...
Analyst ratings
67%
of 30 ratingsMore REGN News
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Tessera Therapeutics, Inc., on Monday announced a global collaboration to develop and commercialize TSRA-196....
Key Points Sales of Regeneron Pharmaceuticals' Eylea have declined over the past few quarters due to competition. However, the company launched a new formulat...
Regeneron Pharmaceuticals and Sanofi recently announced that the European Commission approved Dupixent (dupilumab) for the treatment of moderate-to-severe chron...